Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025. The company is furnishing to U.S. investors two announcements it released to the Australian Securities Exchange on December 15, 2025, including an application for quotation of securities and a cleansing notice.
The materials are provided as exhibits to the Form 6-K and are expressly stated not to be treated as filed for Exchange Act purposes or automatically incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a report as a foreign private issuer to share information it had already released on the Australian Securities Exchange. The report attaches two December 11, 2025 ASX announcements: an application for quotation of securities and a cleansing notice. These documents are furnished to U.S. regulators for information purposes and are not automatically incorporated into other U.S. securities law filings unless specifically referenced later.
Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The attached exhibit, titled “Uniformed Services University to Release Topline Data,” is included as Exhibit 99.1.
The company clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025 to furnish an announcement made to the Australian Securities Exchange. The filing explains that the company published a public notice on December 4, 2025 titled “Change of Share Registry,” which is attached as Exhibit 99.1. The Form 6-K specifies that this information is being furnished, not filed, under U.S. securities laws and will not be incorporated into other securities law filings unless specifically referenced.
Immuron Limited furnished a Form 6-K announcing that it has attached an Australian Securities Exchange notice titled “Proposed issue of securities - IMC.” The filing provides the ASX public notice as Exhibit 99.1 for U.S. investors’ awareness.
The submission is an information update and does not include financial results or transaction terms. It primarily serves to make the ASX announcement available to the U.S. market.
Immuron Limited (IMRN) furnished a Form 6-K announcing it has attached an Australian Securities Exchange notice as Exhibit 99.1. The exhibit is titled “IMM-529 IND approved by FDA”, indicating the company reported an FDA approval of an Investigational New Drug for IMM-529. The ASX announcement was published on November 5, 2025.
The report states it is being furnished, not filed, under the Exchange Act and will not be incorporated by reference into other filings except where expressly referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to an announcement it released on the Australian Securities Exchange. The filing states that the company published a public notice on October 31, 2025 titled “Clinical Trial Update”, and that this announcement is attached to the Form 6-K as Exhibit 99.1. The company also clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other Securities Act filings unless specifically referenced.